An aromatic amide compound having the following general formula (I) is provided:
wherein,
X
1
and X
2
are independently C(O)HN or NHC(O);
G
1
, G
2
and G
3
are independently hydrogen, C(O)HN-phenyl, or NHC(O)-phenyl, wherein at least one of G
1
, G
2
and G
3
is C(O)HN-phenyl or NHC(O)-phenyl;
Q
1
, Q
2
, and Q
3
are independently hydrogen, C(O)HN-phenyl, or NHC(O)-phenyl, wherein at least one of Q
1
, Q
2
, and Q
3
is C(O)HN-phenyl or NHC(O)-phenyl;
R
5
is halo, haloalkyl, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; and
m is from 0 to 4.
Synthetic receptors (H3, H4, H5 and H6) are designed and synthesised for the first time for theobromine, a xanthine alkaloid used as a diuretic. The synthesis of the receptor H6 is achieved by Co(PPh3)3Cl-mediated homocoupling of 3-(ethoxycarbonyl)benzyl bromide 12 under mild conditions. New caffeine receptors (H7, H8 and H9) are designed and synthesised. The binding results of theobromine and caffeine (both by NMR and UV studies) are reported.
selectivity studies of dicarboxylicacids within the cavities of new fluorescent Troger's base molecular frameworks (1-3) have been carried out with a critical examination of their role of rigidity as well as flexibility in selective binding in comparison to receptor 5. The chiral resolution of the racemic Troger's base receptors (1 and 2) by chiral recognition with (+)- camphoric acid using hydrogen-bonding
Copolymers, as well as compounds, compositions, articles of manufacture, and methods of making thereof, are disclosed. The copolymers may generally exhibit flexibility properties and may generally have a high refractive index. The copolymers may generally be made by providing a dihydrodisiloxane and an aliphatic vinyl alcohol and combining the dihydrodisiloxane and the aliphatic vinyl alcohol under conditions that allow for hydrogenation of the aliphatic vinyl alcohol and result in coupling of the aliphatic vinyl alcohol to the dihydrodisiloxane to produce a hydroxyl substituted siloxane.
This invention relates to a pharmaceutical composition comprising a Fc receptor modulating compound and a pharmaceutically acceptable carrier. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating compound.